tbuckley/cabot-search huggingface dataset:
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival
Authors: N. J. Robert, B. Leyland-Jones, L. Asmar, R. J. Belt, D. Ilegbodu, D. M. Loesch, R. N. Raju, M. Cobleigh, K. S. Albain, D. J. Slamom
Journal: Journal of Clinical Oncology (2004)

573 Purpose: This randomized multicenter phase III trial evaluated the efficacy and safety of trastuzumab with paclitaxel 175 mg/m2 and carboplatin AUC=6 (TPC) versus trastuzumab with paclitaxel 175 mg/m2 (TP) in women with HER-2 overexpressing metastatic breast cancer. Methods: Between November 1998 and May 2002, 196 patients (pts) with HER-2 overexpression of 2+ or 3+ by immunohistochemistry were randomized; 188 were eligible; 93 pts received TPC and 95 pts received TP. In both arms, chemotherapy was delivered every 3 weeks for at least 6 cycles and weekly trastuzumab until progression. Results: Overall response (OR) and time to progression (TTP) were significantly improved with TPC compared to TP; OR for TPC was 52%, compared to 36% for TP (P = .04). Median TTP was 11.9 months for TPC and 6.8 months for TP (P = .02). This improvement was greater in HER2 3+ pts, with OR of 57% versus 37% (P = .03), and median TTP of 14.6 months vs 6.9 months (P = .006), for TPC and TP, respectively. There was a trend in the overall survival in favor of TPC of 42.1 months compared to TP with 33.3 months (P= 0.27); in IHC 3+ patients median OS of 42.1 months for TPC vs 30.6 months for TP (P=0.11). Therapy was well tolerated on both arms of the study. Grade 3/4 neutropenia and thrombocytopenia were more common with TPC, as expected. There was no difference in fever/neutropenia, neuropathy, fatigue, and other toxicities between study arms. There was one case of congestive heart failure, seen in the TP arm. Conclusion: The addition of carboplatin to paclitaxel and trastuzumab significantly improved response rate and TTP in pts with a trend to improved overall survival with HER-2 overexpressing metastatic breast cancer. Treatment was well tolerated. Supported by Bristol-Myers Squibb, Plainsboro, NJ. and Genentech, South San Francisco, CA, USA Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb Bristol-Myers Squibb Study support with grants for clinical trials from Bristol-Myers Squibb; clinical trial support from Aventis; clinical trial support from Eli Lilly Bristol-Myers Squibb Bristol-Myers Squibb
AVERAGE CLINICIAN MEASURED BLOOD PRESSURE PREDICT CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES FOLLOWING ACUTE CORONARY SYNDROMES IN THE EXAMINE TRIAL
Authors: William B. White, William Cushman, Stuart Kupfer, George Bakris, Richard Bergenstal, Simon Heller, Cyrus Mehta, Steven Nissen, Faiez Zannad, Yuyin Liu, Christopher Cannon
Journal: Journal of the American College of Cardiology (2017)
Shorter Post-Relapse Survival (PRS) of Myeloma (MM) Patients Randomized to the Thalidomide (T) Arm of Total Therapy 2 (TT2) Related to Chromosome 1q21 Amplification (AMP1Q21, FISH) at Relapse.
Authors: Bart Barlogie, Ichiro Hanamura, Bart Burington, Erik Rasmussen, Peter Stewart, Guido Tricot, Elias Anaissie, Maurizio Zangari, Frits van Rhee, Klaus Hollmig, Teresa Milner, Joshua Epstein, John Crowley, John Shaughnessy
Journal: Blood (2005)
IMPACT OF PLATELET-FIBRIN CLOT STRENGTH ON OCCURRENCE OF IN-STENT RESTENOSIS IN PATIENT WITH DRUG ELUTING STENT
Authors: Min Gyu Kang, Jong-Hwa Ahn, Jeong Yoon Jang, Hyun Woong Park, Jin-Sin Koh, Jeong-Rang Park, Yongwhi Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang, Young-Hoon Jeong
Journal: Journal of the American College of Cardiology (2017)
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy
Authors: X. Steven Xu, Sam Liao, Meletios A Dimopoulos, Pieter Sonneveld, P. Joy Ho, Andrew Belch, Merav Leiba, Marcelo Capra, David Gomez, Eva Medvedova, Shinsuke Iida, Chang-Ki Min, Ming Qi, Jordan Schecter, Nushmia Z. Khokhar, Xiaoyu Yan, Liping Zhang, Pamela L. Clemens
Journal: Blood (2016)
Small Molecule Based Ex Vivo Expansion of CD34+CD90+CD49f+ Hematopoietic Stem &amp; Progenitor Cells from Non-Enriched Umbilical Cord Blood Mononucleated Cells
Authors: Sudipto Bari, Qixing Zhong, Christina LL Chai, Gigi NC Chiu, William YK Hwang
Journal: Blood (2016)
Re
Authors: Mehrbod S. Javadi, Alvaro A. Ordonez, Sanjay K. Jain
Journal: Clinical Nuclear Medicine (2017)

*Russell H. Morgan Department of Radiology and Radiological Science, †Center for Infection and Inflammation Imaging Research, and ‡Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD [email protected] Conflicts of interest and sources of funding: A.A.O. and S.K.J. are supported by the National Institutes of Health (NIH) Director's Transformative Research Award R01-EB020539 (S.K.J.) and R01- HL131829 (S.K.J.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial
Authors: Hamid Sayar, Larry Cripe, Mary Cangany, Jill Weisenbach, Katie J. Sargent, Chirayu Goswami, Lang Li, Annique Wilson-Weekes, Rajasubramaniam Shanmugam, H. Scott Boswell
Journal: Blood (2010)
Reduced Intensity Conditioning Regimen for Allografting Following Autografting Is Feasible and Has a Strong Anti Multiple Myeloma Activity.
Authors: A.M. Carella, Germana Beltrami, Maria T. Corsetti, Potito Scalzulli, Nicola Cascavilla, Michele Carella, Sandro Nati, Mario M. Greco, Pellegrino Musto
Journal: Blood (2004)
The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors
Authors: Elif Hindié
Journal: Theranostics (2017)

Neuroendocrine tumors (NET) are often metastatic at the time of diagnosis.Metastatic well-differentiated (G1/G2) NET may display a wide range of behaviors, ranging from indolent to aggressive, even within apparently homogeneous categories.Thus, selecting the optimal treatment strategy is a challenging task.Somatostatin receptor imaging (SRI) is the standard molecular imaging technique for well-differentiated NET.When performed with 68 Ga-labeled somatostatin analogs (SRI-PET), it offers exquisite sensitivity for disease staging.SRI is also a prerequisite for using targeted radionuclide therapy (e.g. 177Lu-DOTATATE).18F-FDG imaging has traditionally been reserved for staging poorly-differentiated G3 neuroendocrine carcinomas.However, recent data showed that FDG imaging has prognostic value in patients with well-differentiated NET: high uptake was associated with an increased risk of early progression while low uptake suggested an indolent tumor.In this issue of the Journal, Chan and colleagues propose a grading system where the results from the combined reading of SRI-PET and FDG-PET are reported as a single parameter, the "NETPET" score.While the scoring system still needs validation, it is clear that time has come to think about FDG and SRI in metastatic NET not as competitors but as complementary imaging modalities.Dual-tracer imaging can be viewed as a way to characterize disease phenotype in the whole-body.Moving from the prognostic value of dual-tracer imaging to a tool that allows for individualized management would require prospective trials.This editorial will argue that dual-tracer FDG-PET and SRI-PET might influence management of patients with well-differentiated metastatic NET and help selecting between different therapy options.
A prospective clinical study for molecular intra-operative detection of lymph node metastasis in breast cancer patients by one step nucleic acid amplification (OSNA) in comparison to intensive histological investigation
Authors: F. Di Filippo, M. Mottolese, C. Botti, F. Marandino, A. Psaila, P. Perri, S. Di Filippo, R. Pasqualoni, F. Ferranti, S. Buglioni
Journal: Journal of Clinical Oncology (2009)

609 Background: The aims of the study were 1) to assess the accuracy of a new intra-operative molecular diagnostic tool named OSNA, based on the measurement of cytokeratin 19 (CK19) mRNA, in the detection of axillary sentinel lymph node (SLN) metastases in patients with breast carcinoma 2) to determine the concordance of OSNA analysis with multilevel haematoxylin and eosin (H&amp;E) and immunohistochemical (IHC) examination. Methods: A prospective series of 247 consecutive SLNs from 187 breast cancer patients was evaluated. The OSNA assay (Sysmex, Kobe - Japan) follows a short sample preparation step and subsequent rapid amplification of CK19 mRNA based on reverse transcription loop-mediated isothermal amplification. Each SLN was immediately divided into four slices. Two alternate slices were used for the intra-operative OSNA assay. The remaining two slices were investigated by six-level histopathology with 100 μm skip ribbons using routine H&amp;E and CK19 IHC staining. The results of histology and OSNA were then compared. Results: Pts characteristics: infiltrating ductal/infiltrating lobular/mucinous/medullar/DCIS: 130/10/1/1/25. OSNA and histo-pathological methods identified 54 SLNs positive and 185 negative cases (2/3 contained isolated tumour cells). We found 8 discordant cases, 2 OSNA negative with micrometastasis found by IHC/H&amp;E analysis, 5 OSNA positive for micrometastases but IHC/H&amp;E negative and 1 case macrometastatic at OSNA, while negative at IHC/H&amp;E analysis. The overall concordance of OSNA with histopathology was 96.7% with a specificity of 96.8% and sensitivity of 96.4%. These discordances could be due to sampling bias such that a micrometastasis was confined to the slices used for OSNA or the slices used for histology. Conclusions: The current study suggests that the performance provided by OSNA assay is comparable to intensive histopathological work-up even when using only half a lymph node. The method could be applied as a rapid and reliable intra-operative diagnostic tool thus preventing breast cancer patients from a diagnostic delay or second surgery due to a postoperatively diagnosed positive SLN. No significant financial relationships to disclose.
LOWER EICOSAPENTAENOIC ACID TO ARACHIDONIC ACID RATIO IS ASSOCIATED WITH INTRAPLAQUE CHOLESTEROL CRYSTALS: AN OPTICAL COHERENCE TOMOGRAPHY STUDY
Authors: Kazuhiro Fujiyoshi, Yoshiyasu Minami, Ryota Kakizaki, Teruyoshi Nemoto, Sayaka Namba, Takuya Hashimoto, Kentaro Meguro, Takao Shimohama, Minako Yamaoka-Tojo, Taiki Tojo, Junya Ako
Journal: Journal of the American College of Cardiology (2017)
The use of intravenous morphine for breakthrough pain in terminal cancer patients admitted to hospice center.
Authors: Ik-Joo Chung, Sang-Hee Cho, Jun-Eul Hwang, Jae-Sook Ahn, Won-young Choi, Hyun-Jeong Shim
Journal: Journal of Clinical Oncology (2013)

e20621 Background: The adequate opioid dose to be administered for breakthrough pain(BTP) is still controversial. Dosing recommendations are based on patient’s(pts) total daily opioid dose. Intravenous morphine(IV-M) has been found to be effective and safe for the management of BTP. However, physicians are often reluctant in using large doses of IV-M because of the possible adverse events in terminal cancer pts. The aim of this study was to evaluate whether pts were treated appropriately for their BTP in hospice setting. Methods: A total of 94 consecutive terminal cancer pts who were admitted in the Hospice and Palliative Care Clinic at Jeonnam Regional Cancer Center from June 2012 to Nov 2012 were analyzed in this study. Results: In total, 1,213 BTP events treated by IV-M were recorded and the mean number of events per pts was 13.6 (95% confidence interval (CI) 10.5-15.4). The mean dose of IV-M was 13.9mg (95% CI 12.5-14.5mg, range 3-90mg) and was equivalent to 7.1% of the total daily opioid dose. For each episode, pain intensity and opioid-related symptoms were recorded at the base (T0) and within 30 minutes after (T1). Pain intensity decreased from a mean of 5.1(on a 0-10 numeric scale) at base to 1.8 at T1. A decrease in pain of more than 30%, 50% and 70% was observed in 1179 (97.2%), 958 (78.9%) and 460 (37.9%) BTP events, respectively. In 21 episodes, no changes in pain intensity were observed and a further dose of IV-M was given. Doses of more than 10mg, 30mg and 50mg of IV-M were given for 456 (37.6%), 200 (16.5%) and 104(8.6%). No differences in age, sex and pain location were found. Adverse effects were uncommon, moderate nausea/vomiting in 32 episodes, drowsiness in 15 episodes, and confusion in one episode. Conclusions: In the current study, IV-M was safe and effective for almost all episodes of BTP. This study shows that IV-M did not result in life-threatening adverse effects in terminal cancer pts, including older pts and those requiring relatively large doses.
A Multi-Lineage Oral Hemokine™ HQK-1002 Enhances Neutrophil Recovery in Sub-Lethally Irradiated Mice and in Baboons.
Authors: Susan Perrine, Michael Boosalis, Stanley Kosanke, Gary White, Serguei A. Castaneda, Audry Thomson, Hua Cao, Ray Fei, Ronald Berenson, Douglas Faller
Journal: Blood (2009)
Clonal CD57+ Cells in T-Cell Large Granular Lymphocytic Leukemia
Authors: Kseniia A. Sychevskaia, Svetlana Yu. Smirnova, Vadim R. Gorodetskiy, Yulia V. Sidorova, Natalia V. Ryzhikova, Andrey Sudarikov, Valeri G. Savchenko
Journal: Blood (2016)
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline
Authors: Sukhbinder Dhesy-Thind, Glenn G. Fletcher, Phillip S. Blanchette, Mark J. Clemons, Melissa S. Dillmon, Elizabeth S. Frank, Sonal Gandhi, Rasna Gupta, Mihaela Mates, Beverly Moy, Ted Vandenberg, Catherine H. Van Poznak
Journal: Journal of Clinical Oncology (2017)

Purpose To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer. Methods Cancer Care Ontario and ASCO convened a Working Group and Expert Panel to develop evidence-based recommendations informed by a systematic review of the literature. Results Adjuvant bisphosphonates were found to reduce bone recurrence and improve survival in postmenopausal patients with nonmetastatic breast cancer. In this guideline, postmenopausal includes patients with natural menopause or that induced by ovarian suppression or ablation. Absolute benefit is greater in patients who are at higher risk of recurrence, and almost all trials were conducted in patients who also received systemic therapy. Most studies evaluated zoledronic acid or clodronate, and data are extremely limited for other bisphosphonates. While denosumab was found to reduce fractures, long-term survival data are still required. Recommendations It is recommended that, if available, zoledronic acid (4 mg intravenously every 6 months) or clodronate (1,600 mg/d orally) be considered as adjuvant therapy for postmenopausal patients with breast cancer who are deemed candidates for adjuvant systemic therapy. Further research comparing different bone-modifying agents, doses, dosing intervals, and durations is required. Risk factors for osteonecrosis of the jaw and renal impairment should be assessed, and any pending dental or oral health problems should be dealt with prior to starting treatment. Data for adjuvant denosumab look promising but are currently insufficient to make any recommendation. Use of these agents to reduce fragility fractures in patients with low bone mineral density is beyond the scope of the guideline. Recommendations are not meant to restrict such use of bone-modifying agents in these situations. Additional information at www.asco.org/breast-cancer-adjuvant-bisphosphonates-guideline , www.asco.org/guidelineswiki , https://www.cancercareontario.ca/guidelines-advice/types-of-cancer/breast .
Tissue sampling frequency and breast pathology diagnoses following mammography: Time trends and age group analysis from the Breast Cancer Surveillance Consortium (BCSC).
Authors: Kimberly H. Allison, Linn A Abraham, Donald L. Weaver, Anna NA Tosteson, Tracy Onega, Berta M Geller, Karla Kerlikowske, Patricia A Carney, Laura E Ichikawa, Diana SM Buist, Joann G Elmore
Journal: Journal of Clinical Oncology (2013)

559 Background: Pathology diagnoses in a well-characterized population of women can be used to identify tissue sampling and diagnosis trends following mammography. Methods: Screening and diagnostic mammography, patient characteristics, and pathology reports from the BCSC performed from 1996-2008 were identified. Diagnosis was based on the most severe pathology interpretation in the same breast within 60 days of a post-mammogram tissue sample. Age, mammogram year and type, breast density, and family history of breast cancer were evaluated for associations with tissue sampling and most severe pathology diagnosis. Results: 4,022,506 mammograms (88.5% screening; 11.5% diagnostic) were performed in 1,288,886 women; 76,567 (1.9%) were followed by tissue sampling (1.2% screening; 7.1% diagnostic). Tissue sampling frequency following diagnostic mammography increased over time in women over 50 but remained stable following screening mammography. The frequency of invasive cancer increased with age and was more common following a diagnostic (29.3%) vs screening (19.8%) mammogram; the frequency of high risk lesions (ADH; lobular neoplasia) was highest in women aged 50-59. For tissue sampling following screening mammograms, the frequency of DCIS increased over time while benign diagnoses decreased. No significant time trends were noted for diagnoses associated with diagnostic mammograms. Women aged 40-59 with dense breasts and a tissue sampling following screening mammogram had a significantly higher frequency of DCIS (40-49: 4.8% vs 3.2%, P&lt; 0.001; 50-59: 7.0% vs 5.7%, P=0.007). Women aged 40-59 with &gt; 1first degree relative with breast cancer vs none that had a tissue sampling following screening mammogram had a significantly higher frequency of invasive cancer (40-49: 11.4% vs 9.4%, p=0.008; 50-59: 19.8% vs 18.2%, p =0.086) and DCIS (40-49: 6.2% vs 4.0%, p&lt; 0.001; 50-59: 8.2% vs 6.2%, p&lt; 0.001). Conclusions: There was an increase in DCIS and a decrease in benign diagnoses in tissues samples after screening mammography over time. No trends were seen following diagnostic mammography. DCIS was also more frequent in women with dense breasts.
CARDIOPLEGIC ARREST IS ASSOCIATED WITH OVEREXPRESSION OF OPIOID RECEPTORS DELTA AND KAPPA IN DIABETIC AND NON-DIABETIC PATIENTS UNDERGOING ON-PUMP CARDIAC SURGERY
Authors: Tiziano M. Scarabelli, Mahmoud Ismail, Alessio Rungatscher, Mebratu Alebachew Gebrie, Giovanni Battista Luciani, Riccardo Raddino, Louis Saravolatz, Carol Chen-Scarabelli, Giuseppe Faggian
Journal: Journal of the American College of Cardiology (2017)
A cross-section study evaluating patients’ satisfaction with totally implanted access ports (PAC) assessing the PAC-related complication rate at two tertiary care centres in Austria.
Authors: Christoph Minichsdorfer, Thorsten Fuereder, Bruno Maehr, Anna Sophie Berghoff, Anna catharina Dressler, Michael Gnant, Christoph Zielinski, Rupert Bartsch
Journal: Journal of Clinical Oncology (2014)

e17574 Background: Totally implanted access ports (PACs) have become valuable tool for the administration of chemotherapy in cancer patients. Methods: During the period from November 2012 to August 2013, patients were invited to answer a questionnaire concerning quality-of-life and satisfaction with their respective PAC devices. Retrospectively data regarding PAC-related complications were collected, by searching patients’ medical history. Results: 202 patients with a total number of 230 PAC devices were included at two tertiary medical care centres in Austria. Median time from PAC implantation to inclusion was 9 months (range 1-148 months). Early complications occurred in 31 cases (13,5%), with bleeding and haematoma being the most frequently observed events; five patients developed postsurgical pneumothorax (2.2%). Late complications consisted of infections (twelve cases; 5.2%), drug extravasation (five cases; 2.2%), PAC malposition (four cases; 1.7%), PAC malfunction (ten cases; 4.45%) and thrombosis (four cases; 1.7%). In total, 28 PAC systems had to be removed due to adverse events. One fifth of all patients reported that their PAC interfered with activities of daily life. On the other hand, 180 patients (87.1%) agreed that PAC systems alleviated the administration of chemotherapy. Indeed, the vast majority (87.1%) would once again choose a PAC system for chemotherapy administration. Conclusions: PAC devices important tools for safe administration of intravenous therapy in cancer patients. Most important they do not substantially interfere with patient activities and are widely accepted. Nevertheless, complications may occur which can lead to loss of the PAC device.
Epithelioid angiomyolipoma of the liver: a case report
Authors: Soo Yeon Lee, Baek-hui Kim
Journal: Clinical and Molecular Hepatology (2017)

Epithelioid angiomyolipoma (EAML) of liver is a rare neoplasm. Hepatic EAML is often misdiagnosed as other neoplasms such as hepatocellular carcinoma due to non-specific clinical and radiologic features. The morphologic features under microscope and immunohistochemistry staining profile are important in the diagnosis EAML. Here, we report a case of 52-year-old man who found 1.2 cm mass in liver by routine checkup. On the impression of hepatocellular carcinoma, lateral sectionectomy of the liver was done. Microscopically, the tumor is composed of predominant epithelioid cells with vascular component and foamy cells. These cells were positive for HMB45, MelanA, and smooth muscle actin and negative for epithelial membrane antigen. The final diagnosis was hepatic EAML. Keywords: Liver; Angiomyolipoma; Perivascular epithelioid cell neoplasms
Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma
Authors: David M. Kurtz, Florian Scherer, Aaron M Newman, Alexander Craig, Michael Jin, Henning Stehr, Jacob J. Chabon, Mohammad Esfahani, Chih Long Liu, Li Zhou, Cynthia Glover, Brendan C. Visser, George Poultsides, Ranjana H Advani, Lauren S Maeda, Neel K. Gupta, Ronald Levy, Robert S. Ohgami, R Eric Davis, Christian A. Kunder, Jason R. Westin, Maximilian Diehn, Ash A. Alizadeh
Journal: Blood (2016)
Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients
Authors: Qian Shi, Norbert Schmitz, Christopher Flowers, Fang-Shu Ou, David Cunningham, Michael Pfreundschuh, John F Seymour, Ulrich Jaeger, Thomas M. Habermann, Corinne Haioun, Hervé Tilly, Herve Ghesquieres, Francesco Merli, Marita Ziepert, Raoul Herbrecht, Jocelyne Flament, Tommy Fu, Bertrand Coiffier, Daniel Sargent
Journal: Blood (2016)
Antidrug Antibodies in Patients Treated with Alirocumab
Authors: Eli M Roth, Anne C Goldberg, Alberico L Catapano, Albert Torri, George D Yancopoulos, Neil Stahl, Aurélie Brunet, Guillaume Lecorps, Helen M Colhoun
Journal: New England Journal of Medicine (2017)

In 10 clinical trials involving 4747 patients, among those who received the PCSK9 inhibitor alirocumab, antidrug antibodies developed in 5.1%, although no significant effect was seen on the reduction in LDL cholesterol levels.